Axsome Initiates Solriamfetol Phase 3 in Adolescent ADHD; Thesis Remains Cautious

What happened

Axsome Therapeutics dosed the first patient in the FOCUS-3 Phase 3 trial of solriamfetol for adolescents with ADHD, expanding the asset's label potential. However, the DeepValue report highlights that prior Sunosi (solriamfetol) trials in adult ADHD and depression yielded mixed or negative results, raising doubts about this indication's prospects. At ~$188, the stock already prices in continued strong Auvelity growth and successful AXS-05 Alzheimer's agitation approval by April 2026, leaving limited upside. The new trial does not alter the near-term risk-reward skew, as any data readout is years away and does not offset the company's concentrated revenue base and negative earnings. Investors should watch the April 30 PDUFA for AXS-05 and Auvelity prescription trends for signals that could shift the narrative, rather than this early-stage expansion.

Implication

While the trial expands solriamfetol's addressable market, previous ADHD failures and the stock's rich valuation keep risk-reward skewed negatively. Investors should focus on the April PDUFA for AXS-05 and Auvelity growth trends rather than early-stage pipeline moves.

Thesis delta

The news does not materially change the investment thesis. The DeepValue report's negative skew remains intact as solriamfetol's ADHD history is mixed. This trial is a long-duration option with low near-term impact.